Updates on risk of uterine perforation with intrauterine devices

Bayer is informing healthcare professionals of recently available safety information from a large prospective, comparative, non-interventional cohort study using intra-uterine devices. The “European Active Surveillance Study for Intrauterine Devices” (EURAS-IUD) study showed that there is a higher risk of uterine perforation in breastfeeding women and also in women who are up to 36 weeks post-partum at the time of insertion for both levonorgestrel-intrauterine system (LNG-IUS) and copper IUDs (Cu IUDs). Healthcare professionals are recommended to take this information into consideration when selecting IUDs for use in patients who are less than 36 weeks post-partum or breastfeeding at the time of insertion.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.